-
Debate will tackle optimal method for tracking burden and severity of hypoglycemia
Gregg Simonson, PhD, and other experts will review the evidence, share their insights, and engage in a robust debate highlighting objective measurements of hypoglycemia as well as subjective patient-reported events.
-
Speakers will highlight timely topics in nutrition and diabetes
Dietitian Maya Feller, MS, RD, CDN, and other experts will examine people’s relationships with food, as well as how low-carb, low-fat, and plant-based diets affect disease management and overall health.
-
Scientists to discuss multi-faceted approach to managing CV risk in people with diabetes and ASCVD
Irl Hirsch, MD, and other speakers will highlight considerations related to lipid management, glycemic metrics, and inflammation in this population, including clinical considerations not currently addressed in standard treatment guidelines.
-
Symposium to highlight first ADA Standards of Care for Overweight and Obesity
Fatima Cody Stanford, MD, MPH, MPA, MBA, MACP, and others will detail some of the considerations for the management of these chronic conditions, including weight stigma and pharmacotherapy options. The new standards of care will be published later this year.
-
Panel will discuss approaches for screening and primary prevention of ASCVD in diabetes
Ian H. de Boer, MD, MS, and other panelists will explore blood pressure targets, glucose-lowering drugs, aspirin use, various screenings, and their roles in preventing and diagnosing atherosclerotic cardiovascular disease.
-
Speakers will explore intersection of circadian biology and diabetes
Experts, including Satchidananda Panda, PhD, will discuss the role of the circadian clock in modulation of beta cell function and glucose homeostasis, and spotlight the benefits of time-restricted eating.
-
Session to review strengths and limitations of CGMs and their data
Michael Kohn, MD, MPP, and other experts will delve into the controversies surrounding continuous glucose monitoring and its overall positive impact on the care for people with diabetes.
-
Researchers to present CV findings from SOUL trial of oral semaglutide in high-risk type 2 diabetes
Investigators, including John B. Buse, MD, PhD, will detail the key findings of a study to determine whether a new oral formulation of semaglutide is a safe and effective alternative to the injectable formulation.
-
Symposium will highlight major STRIDE forward in treating PAD alongside type 2 diabetes
Subodh Verma, MD, PhD, FRCSC, will share key results from a clinical trial using semaglutide in patients with type 2 diabetes and peripheral artery disease.
-
ADA Symposium to review year’s important advances in diabetes research
Martin G. Myers, Jr., MD, PhD, will provide a year in review of basic science discoveries. Jennifer Green, MD, will look back at clinical research. Eric Ravussin, PhD, will summarize breakthroughs in translational diabetes research.